Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49,625,327
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
6,345,954
-
Shares change
-
-328,072
-
Total reported value, excl. options
-
$20,561,000
-
Value change
-
-$1,159,878
-
Number of buys
-
6
-
Number of sells
-
10
-
Price
-
$3.24
Institutional Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q2 2022
As of 30 Jun 2022 Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) had 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 6,345,954 shares of stock of the company.
Largest 10 holders included Northpond Ventures, LLC, FRANKLIN RESOURCES INC, FMR LLC, Sands Capital Ventures, LLC, Point72 Asset Management, L.P., VANGUARD GROUP INC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This table shows 24 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.